You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Discontinuing risperidone results in relapse in children with autism spectrum disorders

http://dx.doi.org/10.1136/ebmh.9.2.56

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137–44.OpenUrlCrossRefPubMedWeb of Science

    Q Does risperidone prevent relapse compared with placebo for children with autism spectrum disorders?

    METHODS

    Embedded ImageDesign:

    Randomised controlled trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Double blind.

    Embedded ImageFollow up period:

    Thirty two weeks.

    Embedded ImageSetting:

    Groningen and Utrecht University Child and Adolescent Psychiatry Centres; time period not stated.

    Embedded ImagePatients:

    Thirty six children aged 5–17 years with an autism spectrum disorder (Autism Diagnostic Interview-Revised plus clinical judgement) enrolled in the open label phase, 24 children who responded to risperidone were randomised. Other enrolment criteria: at least moderate disruptive behaviour (tantrums, self-injury, and/or aggression) …

    View Full Text

    Footnotes

    • For correspondence: Dr Pieter W Troost, Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; p.troost{at}accare.nl

    • Source of funding: Korczak Foundation.